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REVIEW
Abstract: Anticholinergics are commonly used in primary and secondary care settings for 
the treatment of overactive bladder syndrome. The number of anticholinergic drugs available 
on the market is increasing and various studies, both observational and randomized controlled 
trials, have evaluated effectiveness of the different preparations available. When anticholinergic 
therapy is prescribed, there is still uncertainty about which anticholinergic drugs are most 
effective, at which dose, and by which route of administration. There is also uncertainty about 
the role of anticholinergic drugs in different patient groups, particularly in the elderly. The 
rationale for using anticholinergic drugs in the treatment of overactive bladder syndrome is 
to block the parasympathetic acetylcholine pathway and thus abolish or reduce the intensity 
of detrusor muscle contraction. There are currently ﬁ  ve recognized subtypes of muscarinic 
receptor; the M1, M2, and M3 subtypes are of interest in bladder activity. Muscarinic receptors 
are found in other parts of the body, eg, in the gut, salivary glands, tear ducts. Side effects 
associated with non-selective antimuscarinics can be particularly distressing in the elderly. 
The development of bladder selective M3 speciﬁ  c antagonists has the advantage of providing 
increased efﬁ  cacy with minimal side effects. Darifenacin is one such preparation. The aim 
of this review is to assess the pharmacology, interactions and the safety and tolerability of 
darifenacin in the treatment of overactive bladder in the elderly population with particular 
reference to clinical trial data available.
Keywords: darifenacin, antimuscarinics, overactive bladder, detrusor overactivity, urinary 
incontinence
Introduction
Overactive bladder (OAB) is a common condition characterized by urinary urgency, 
with or without urge incontinence usually with frequency and nocturia (Abrams et al 
2002). Epidemiological studies from the US have reported the prevalence of OAB to 
be 16.9% (Stewart et al 2003); it can affect men and women alike, but the prevalence 
increases with age. OAB can have a detrimental effect on physical functioning and 
psychological well-being, as well as signiﬁ  cantly reducing quality of life (Abrams et 
al 2000). In patients under 25 the prevalence is 4.8% and in those over the age of 65 
years 30.9% (Milsom et al 2001; Stewart et al 2003). In the elderly the commonest 
manifestation is urinary incontinence (Castleden et al 1981).
Antimuscarinic drug therapy, in conjunction with behavioral therapy such as 
bladder retraining, remains the ﬁ  rst line of management in patients with irritative 
bladder symptoms or OAB. Several antimuscarinic agents are currently available for 
the treatment of OAB in adults. The antimuscarinics all appear to exert their clinical 
effect through inhibition of the bladder muscarinic receptors, but they vary in their 
functional proﬁ  le and can be associated with troublesome side effects such as dry 
mouth, constipation, somnolence, and blurred vision. In a questionnaire follow-up study 
of women with detrusor overactivity, just 5.5% were cured of their urinary symptoms 
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and only 18.2% of women continued drug therapy for more 
than 6 months (Kelleher et al 1997). The development of 
relatively bladder selective antimuscarinic drugs such as 
tolterodine has helped to reduce adverse effects, but the 
development of darifenacin and the recent marketing of 
solifenacin represent the ﬁ  rst highly selective bladder speciﬁ  c 
anti-muscarinic (M3 speciﬁ  c antimuscarinics) agents for the 
management of OAB.
While efﬁ  cacy of antimuscarinics has been demonstrated 
in adult populations (including patients >65 years of age), 
few studies have been reported speciﬁ  cally in a geriatric 
population, and antimuscarinics are often underutilized in 
the elderly despite the marked increase in the prevalence of 
OAB in this age group. One explanation for this apparent 
under-use of an effective treatment option may be concerns 
about the frequency of anticholinergic adverse events, such 
as dry mouth; the likelihood of detrimental central nervous 
system (CNS) effects, including cognitive impairment and 
sleep disturbances; and the potential for harmful interactions 
with existing pharmacotherapy. 
Muscarinic receptors and effects of 
aging
Molecular cloning studies have revealed the existence of 
five genes for muscarinic receptors in rats and humans. 
This corresponds to five subtypes of muscarinic receptors, 
M1– M5 (Caulfield and Birdsall 1998). The distribution 
of the different subtypes in the human body varies and 
so does their functional importance. Table 1 shows the 
distribution of different muscarinic receptors in the 
body.
Detrusor muscle from various species including man 
contains M2 and M3 receptors. Although the M2 receptors 
predominate (approximately M2:M3:2:1), in humans it is 
the M3 receptors that are thought to cause a direct muscle 
contraction via phosphoinositide hydrolysis (Harriss et al 
1995), whereas M1 receptors have never been demonstrated 
(Yamaguchi et al 1996). It is thought that the M3 receptor is 
responsible for the normal micturition contraction (Caulﬁ  eld 
and Birdsall 1996). The M2 receptors may become more 
important in mediating detrusor contractions in certain 
disease states such as neurogenic bladder dysfunction 
(Braverman et al 1998). 
Animal studies show there is no change in the relative 
abundance of M2 and M3 receptors with advancing age; this 
is accompanied by only minor if any alterations in receptor 
responsiveness (Schneider et al 2005).
Pharmacology: darifenacin 
Darifenacin is a highly speciﬁ  c M3 receptor antagonist which 
is used in the US and Europe, and is yet to be launched in the 
UK. It has been shown to have a higher degree of selectivity 
for the M3 receptors (Tables 2 and 3) than the commonly 
used antimuscarinics currently available and has activity 
both in vitro (Wallis 2006) and in vivo (Quinn 2006). It may 
be expected that drugs selective for the M3 receptors in the 
bladder have greater clinical efﬁ  cacy in detrusor overactivity. 
It has also been shown to have a reduced adverse side effect 
proﬁ  le (Anderson 2006). 
Darifenacin was acquired by Novartis in May 2003 and 
is expected to be marketed as Enablex in the UK in the near 
future.
Effects in vivo
In bladder and salivation models of conscious rats, 
darifenacin has been compared with oxybutynin (Williamson 
et al 2006). The micturition interval and volume as well as 
the peak micturition pressure were assessed before and an 
Table 1 Distribution of muscarinic receptors
Subtypes   Distribution 
M1    Brain (cortex, hippocampus), sympathetic ganglia, glands  
M2    Heart, smooth muscle, hindbrain  
M3    Smooth muscle, glands, brain 
M4    Brain (forebrain, striatum) 
M5    Brain (substantia nigra), eye 
Table 2 Afﬁ  nity (pKi) of antimuscarinic compounds for the 
human recombinant receptor subtypes M1– M5 (Anderson 2006) 
(Mean)
   M 1   M 2   M 3   M 4   M 5 
Darifenacin   8.2     7.4     9.1     7.3     8.0     
Oxybutynin     8.7       7.8     8.9     8.0     7.4   
Tolteridine   8.8     8.0     8.5     7.7     8.0   
                
Propiverine   6.6       5.4     6.4     6.0     6.5   
Trospium   9.1     9.2         9.3     9.0     8.6   
Table 3 Comparison of M3:M1 selectivity of the antimuscarinic 
compounds (Napier and Gupta 2002)
   M 3 versus M1   P 
Darifenacin   9.3   <0.001 
Tolteridine   0.6
a    <0.05 
Oxybutynin   1.5
b    <0.05 
Propiverine   0.6
a    <0.05 
Trospium   1.5   NS 
Notes: 
aSigniﬁ  cant selectivity for M1, but unlikely to be biologically signiﬁ  cant; 
bSigniﬁ  cant, but unlikely to be biologically relevant.Clinical Interventions in Aging 2006:1(4) 311
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hour after injection with the test compound (darifenacin 
0.1–0.3 mg/kg; oxybutynin 0.1–3.0 mg/kg). Dose-related 
decreases were seen in all micturition parameters, 
which were significantly greater than those seen with 
oxybutynin (p<0.05), although the effect was equipotent 
on salivation. 
Effects on CNS
The side effects of antimuscarinics on the CNS have been 
well documented. Adverse effects such as somnolence 
and cognitive impairment are a result of M1 blockade in 
the brain. The role of M1 receptors in cognitive function is 
well accepted, and is the basis of the therapeutic principle 
in the treatment of Alzheimer’s disease (Anderson 2006). 
The elderly therefore are particularly at risk of cognitive 
side effects with non-speciﬁ  c antimuscarinics hence the 
reluctance to use them in the elderly population. 
To assess the effects of darifenacin controlled-release 
and oxybutynin extended-release (ER) on cognitive function 
(particularly memory) 150 patients ≥60 years old, were 
randomized to darifenacin, oxybutynin ER or placebo in a 
multicenter, double-blind, double-dummy, parallel-group, 
3-week study (Kay et al 2006). Doses were administered 
according to US labels: oxybutynin ER 10 mg once daily 
(od), increasing to 15 mg od in weeks 1 and 2, then 15 mg 
od in week 3. The primary end point was accuracy on the 
Name-Face Association Test (delayed recall) at week 3. 
While darifenacin had no signiﬁ  cant effects on memory 
versus placebo, oxybutynin ER caused signiﬁ  cant memory 
deterioration (magnitude of effect comparable with brain 
aging of 10 years).
Similar studies in younger populations testing the effects 
of darifenacin on cognitive function at doses of 7.5 mg 
or 15 mg, did not produce any detectable effects relative 
to placebo (Nichols et al 2006). The sparing of cognitive 
function in relation to the use of darifenacin (and trospium) 
is an attractive result of the M1-sparing effect of darifenacin 
and is therefore potentially very useful in the elderly.
Effects on the cardiovascular system and 
the electrocardiogram
A study in the chioralose–urethane anesthetized beagle dog 
assessed the potency of darifenacin, tolterodine, oxybutynin, 
and propiverine on pelvic nerve-stimulated bladder 
contractions, trigeminal nerve stimulated salivation, and 
heart rate (Gupta et al 2006). Darifenacin did not increase 
the heart rate at doses required to maximally inhibit bladder 
contractility (100 μg/kg), whereas tolterodine increased heart 
rate at doses within the range needed to inhibit contractility. 
In the study by Nichols and colleagues (2006), darifenacin 
(7.5 mg and 15 mg) had no signiﬁ  cant effect on heart rate or 
heart rate variability, whereas dicyclomine (dicycloverine) 
signiﬁ  cantly reduced heart rate (−4.79 bpm, p=0.003) and 
increased variability (12%, p=0.005) compared with placebo. 
No changes in either the vital signs or electrocardiogram 
(ECG) were found to be due to darifenacin. Prolongation of 
QT interval on an ECG is a valuable predictor of a drug’s 
ability to cause potentially fatal ventricular tachyarrhythmia. 
Serra and colleagues (2005) found there was no signiﬁ  cant 
increase in QT interval with darifenacin treatment compared 
with placebo.
Pharmacokinetics 
The pharmacokinetics of darifenacin have been determined 
in human volunteers after oral administration of the drug 
and studied in animal models after oral and intravenous 
administration (Beaumont et al 1998). Pooled data have 
been used to model population pharmacokinetics (Kerbusch 
et al 2003). Plasma concentrations were calculated using 
(Anderson 2006) C-labelled darifenacin 5 mg dose, after 5 
days of achieving a steady-state plasma concentration.
Darifenacin is well absorbed in humans. Unchanged 
darifenacin is present in very small amounts in the feces, 
showing that it is almost completely absorbed from the 
gastro-intestinal tract (Beaumont et al 1998). Compared with 
immediate release preparations, higher bioavailability has 
been noted with extended release preparations (Kerbusch 
et al 2003). This may be due to differing activity of the 
metabolizing mechanisms in the lower intestinal tract 
(Paine et al 1997). Food has no effect on absorption 
(Nichols 2006).
Darifenacin is highly protein-bound in the plasma (>96% 
in all species tested; 98% in man) (Beaumont et al 1998). 
Volumes of distribution are higher than body water in the 
animal models after intravenous administration (12 L/kg, 
7 L/kg, and 6.8 L/kg in mouse, rat, and dog, respectively).
Darifenacin has an efﬁ  cient hepatic metabolism (Beaumont 
et al 1998) and this is demonstrated by plasma clearance 
values that are high relative to hepatic blood ﬂ  ow. This leads 
to a short half-life in man. Darifenacin has three principal 
mechanisms of metabolism: monohydroxylation in either the 
dihydrobenzfuran or diphenylacetamide moieties; opening of 
the dihydrobenzfuran ring; or N-dealkylation at the pyrrolidine 
nitrogen. The main metabolite, UK-148993
 (Beaumont 
et al 1998), is formed primarily through hydroxylation 
of darifenacin by cytochrome P4503A4 (CYP3A4) Clinical Interventions in Aging 2006:1(4) 312
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and cytochrome P4502D6 (CYP2D6) and is 50-fold less 
potent than the parent drug (Kerbusch et al 2004). There is a 
great deal of polymorphism in CYP2D6, and individuals with 
poor CYP2D6 metabolism may have higher plasma levels 
of the drug, with 20% reduction in clearance of the drug, 
and 52% increase in bioavailability (Kerbusch et al 2003) 
when compared with homozygote extensive metabolizers. 
Japanese subjects have a 56% lower availability of 
darifenacin than Caucasians (Kerbusch et al 2003). No other 
racial differences in bioavailability were seen, indicating that 
the difference is due to increased ﬁ  rst pass metabolism in 
the liver (by CYP3A4 and CYP2D6). Distribution of alleles 
pertaining to CYP2D6 is known to differ between Japanese 
and Caucasian races (Xie et al 2001), but when the CYP2D6 
activity was controlled for separately, and knowing that no 
ethnic differences seem to exist in CYP3A4 activity (Xie 
et al 2001), it appears that other as yet unidentiﬁ  ed factors 
are involved. Women have a 31% lower rate of clearance 
of darifenacin than men (Kerbusch et al 2003), which is 
felt to be due to a lower activity of CYP2D6 in women 
(Tanaka 1999) and which would seem therefore to draw 
parallels with the CYP2D6 poor-metabolizers previously 
alluded to (despite a higher activity of CYP3A4 in women 
[Tanaka 1999]). Biotransformation by the cytochrome P450 
(CYP450) system is an important step in the activation 
or elimination of a large number of drugs, including 
oxybutynin, tolterodine, darifenacin, and solifenacin, raising 
the possibility of clinically relevant and potentially serious 
drug interactions. In elderly patients, such interactions are of 
particular relevance given the potential for declining activity 
of certain members of the CYP450 family combined with 
decreased hepatic blood ﬂ  ow, which can reduce ﬁ  rst-pass 
metabolism and thus the bioavailability of drugs metabolized 
via this route. 
After administration of 14C-labelled darifenacin, most 
of the radioactive dose was recovered within 48 h, balanced 
between urine and feces in humans (Beaumont et al 1998). 
Approximately 44% of a dose was recovered from the feces 
and 58% from the urine, in both cases predominantly as 
metabolites.
Drug interactions
Data assessing drug and food interactions of darifenacin 
are relatively scarce. Kerbusch and colleagues (2003) 
have looked at the effect of ketoconazole (an azole used 
in the treatment of fungal conditions) and erythromycin 
(a macrolide antibiotic) on the metabolism of darifenacin. 
Both of these agents are CYP3A4 inhibitors, although 
ketoconazole is 50 times more potent than erythromycin. Use 
of ketoconazole reduced clearance of darifenacin by 68% 
(Kerbusch et al 2003) and increased the bioavailability of 
the drug to 100%. Erythromycin had no effect on clearance 
but increased bioavailability to 97%. Ketoconazole and 
erythromycin also affected levels of the active darifenacin 
metabolite, although this was thought to be due to a reduction 
in metabolism from the parent drug, rather than an increase 
in clearance of the metabolite.
Caution is therefore warranted in the use of darifenacin 
in patients taking CYP3A4 inhibitors. Potent inhibitors 
should be avoided in view of their combined effect on 
clearance and metabolism. Higher doses of darifenacin are 
generally well tolerated, and so modest increases in drug 
concentration with less potent inhibitors are not clinically 
relevant.
Efﬁ  cacy studies 
Darifenacin has been the subject of several well conducted 
and extensive trials with rigorous entry criteria. Analysis of 
pooled data from three such studies enrolled 1059 patients 
(85% of whom were female; age range 19–88 years) with 
at least 6-month history of overactive bladder symptoms 
(urgency, frequency, and urge incontinence) (Chapple et 
al 2005). All had a 2-week washout and a 2-week placebo 
run-in, prior to commencing active participation. Participants 
were randomized to receive either darifenacin-controlled 
release 7.5 mg or matched placebo (n=335/271, respectively) 
or darifenacin controlled release 15 mg or matched placebo 
(n=330/384, respectively). Outcome data were collected 
by use of an electronic diary (hand-held computerized 
diaries have been developed to overcome the lack of patient 
compliance that has been noted in many studies [Rabin 
et al 1993]; patients felt that their symptoms were more 
properly reﬂ  ected by the computerized version, felt more 
motivated to provide data, and found it easier to remember 
to enter data).
Both doses of darifenacin were signiﬁ  cantly superior 
to placebo in alleviating the symptoms associated with 
OAB (Table 4), however, a marked placebo response 
was noted. Darifenacin (15 mg controlled release) has 
also been compared with oxybutynin (5 mg TDS) and 
matched placebo (Zinner et al 2005). Seventy-six patients 
(93% female) had detrusor overactivity (urodynamically 
veriﬁ  ed OAB) with ≥4 urinary incontinence (UI) episodes 
per week and a frequency of >8 micturitions per day; all Clinical Interventions in Aging 2006:1(4) 313
Darifenacin in the elderly
underwent a 2-week run-in period prior to 2 weeks of 
treatment in each arm, in a randomized sequence. Outcomes 
were assessed using a paper diary (Table 5). The results 
revealed comparable efﬁ  cacy with oxybutynin, in terms of 
signiﬁ  cant improvement of the major symptoms of OAB, 
when compared with placebo. 
Rapid onset of action of darifenacin is a useful attribute 
and has been assessed in a well conducted study (Haab et al 
2004). In this study, 561 patients (age range 19–88 years; 
85% female) were enrolled with OAB symptoms of more 
than 6-month duration. After a 2-week washout and a 2-
week placebo run-in, the participants were randomized in 
a 1:4:2:3 ratio to 3.75 mg darifenacin, 7.5 mg darifenacin, 
15 mg darifenacin, or placebo. Significant and rapid 
onset of action was noted by 2 weeks, although evolving 
benefit was seen up to 12 weeks in this study. Benefits to 
patients taking darifenacin have been shown, not only in 
terms of symptom improvement but also by demonstrable 
improvements in quality of life, as assessed by the King’s 
Health Questionnaire (Chapple 2006). The low incidence 
of cognitive side effects has been discussed as a benefit 
in the elderly. Efficacy in an elderly population has been 
studied by Foote and colleagues (2005), by analysis of 
pooled data. This included 317 patients aged 65 years or 
more, in one of three multicenter, randomized, double-
blind, placebo controlled studies. All had OAB symptoms 
of more than 6-month duration. All had a 2-week washout 
(only if needed) and a 2-week drug-free/placebo run-
in, prior to receiving once daily orally administered 
controlled-release darifenacin 7.5 mg (n=97) and matching 
placebo (n=72), or controlled-release darifenacin 15 mg 
(n=109) and matching placebo (n=108). At 12 weeks, 
both doses of darifenacin were significantly superior 
to placebo (p<0.05) in improving all OAB parameters 
studied, confirming efficacy in an elderly population 
(Table 6).
Safety and tolerability
The proposed doses of darifenacin are 7.5 mg or 15 mg and 
in studies reporting safety and tolerability these doses been 
well tolerated (Kirwin 2006). Side effects are generally 
dose-related and of mild-to-moderate severity when they 
occur.
Chapple and colleagues (2005) report the commonest side 
effects to be dry mouth (7.5 mg 20%; 15 mg 35%; placebo 
8%) and constipation (7.5 mg 15%; 15 mg 21%; placebo 
6%), although these resulted in low rates of discontinuation 
(7.5 mg 0.6%; 15 mg 2.1%; placebo 0.3%). On the other 
hand, CNS and cardiovascular safety were comparable 
with placebo. Different studies report similar ﬁ  ndings with 
regard to side effects proﬁ  le. Zinner and colleagues (2005) 
in their comparison of darifenacin (15 mg QD), oxybutynin 
(5 mg TDS) and placebo also conﬁ  rmed dry mouth and 
constipation as the commonest side effects of darifenacin. 
Dry mouth was 36.1% in the oxybutynin arm compared with 
13.1% of darifenacin patients (p<0.05) and 4% in the placebo 
group (p<0.05). Rates of constipation were comparable in 
Table 4 Outcomes comparing darifenacin or matched placebo after 12 weeks of treatment (Chapple et al 2005)
   Darifenacin(%)  Placebo  (%)   Darifenacin(%)   Placebo  (%) 
   (7.5 mg QD)     (15 mg QD)   
Incontinence episodes /week    −8.8(−68.4)
*    −7(−53.8)    −10.6(−76.8)
**    7.5 (−58.3) 
Incontinence episodes resulting in pad change    −4(−77.1)    −2(−47.7)    −4.8(−78.6)
**    −2.7(−55.1) 
Frequency of urgency/day    −2(−29)
**    −1(−14.3)    −2.3(−29)
**    −1.2(−16.7) 
Micturition Frequency/day    −1.6(−16.6)
**    −0.9(−9.1)    −1.9(−17.4)
**    −1(−9.9) 
Bladder capacity (mean vol void:ml)   15.4(9.6)
*    7.6(4.9)   26.9(17.5)**   5.9(3.9)   
Severity of urgency    −7.8(−14.2)
**    −4.2(−7.8)    −9.3(−16.1)
**    −4.5(−8) 
Notes: Results expressed as median (%) change from baseline, at week 12; 
*p<0.01; 
**p<0.001 (Wilcoxon rank-sum test). 
Table 5 Comparison of 2 weeks treatment outcomes of 
darifenacin, oxybutynin, or placebo (Zinner et al 2005)
   Darifenacin    Oxybutynin  Placebo
 (n=58)   (n=58) 
 15 mg QD   5  mg TDS     (n=58) 
Micturition/day   9.33   9.24   9.62 
Incontinence   10.93
*    9.45
*    14.64   
episodes/week   
Urgency episodes/day   7.95
*    8.12
*    8.71 
Severity of urgency   1.93
*    1.89
*    2.03 
episode
**   
Notes: Evaluable patients (n=58). Values shown are means adjusted for sequence 
and period from the crossover analysis of variance; 
*p<0.05 vs placebo, accounting 
from multiplicity by least signiﬁ  cant difference method; **1=mild, 2=moderate, 
3=severe. 
Abbreviations: QD, once daily; TDS, three times dailyClinical Interventions in Aging 2006:1(4) 314
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darifenacin (10%) and oxybutynin (8%) and signiﬁ  cantly 
higher than placebo (3%, p<0.05). Most of the side effects 
were mild to moderate in both groups; no patients in the 
darifenacin group discontinued treatment. There were no 
clinically relevant, treatment-emergent changes in blood 
pressure, pulse rate, or ECG. Dizziness and blurred vision 
were reported in patients taking oxybutynin. 
In a comparison with tolterodine immediate-release (Foote 
2006), dry mouth was the commonest side effect (darifenacin 
7.5 mg 20.2%; darifenacin 15 mg 35%; tolterodine 26.9%; 
placebo 8%) in all groups. Constipation (darifenacin 7.5 mg 
14.8%; darifenacin 15 mg 21%; tolterodine 10.3%; placebo 
5.4%) and dyspepsia (darifenacin 7.5 mg 1.8%; darifenacin 
15 mg 7.5%; tolterodine 7.6%; placebo 1.5%) were also 
reported. Dizziness and somnolence were reported, but the 
numbers were very small and no signiﬁ  cant differences were 
detected in the different groups. All reported side effects are 
transient and tolerable. Even though constipation is one of 
the commonest side effects, the use of laxatives and stool 
softeners is low and comparable with their use in the placebo 
groups. Treatment-related adverse events infrequently lead to 
withdrawal (Steers et al 2005). Studies to date have excluded 
patients with hepatic disease (Haab et al 2004) in keeping 
with the nature of the metabolism of darifenacin. However, 
pharmacokinetic analyses have shown a 4.7-fold increase 
in drug concentrations with moderate hepatic impairment 
(Croom and Keating 2004). If being used, dose adjustment 
of darifenacin would be necessary in this group of patients. 
No clinically signiﬁ  cant change in dose concentrations arose 
as a result of mild hepatic impairment, or renal impairment 
of varying degrees (Croom and Keating 2004), and so no 
dose adjustment is necessary.
Patient perspectives
Urinary incontinence is an important contributor to 
the complications and economic cost of OAB for both 
community-dwelling and institutionalized elderly individuals. 
Many patients with OAB do not seek treatment because of 
embarrassment, fear of surgery, or the misperceptions that 
the problem is untreatable, or is a normal and inevitable 
consequence of aging. Nonpharmacological therapies 
improve bladder control by modifying lifestyle and behavior 
to prevent urine loss. This requires patient and caregiver 
motivation and can be time consuming. However optimal 
results may be obtained by combining these strategies 
with pharmacotherapy or by means of pharmacotherapy 
alone. Important considerations for elderly patients include 
tolerability, absence of drug interactions, and the availability 
of a range of dosages to tailor treatment to individual patients. 
As demonstrated in this review of literature, darifenacin 
favorably fulﬁ  lls these criteria. These results are supported 
by signiﬁ  cant improvements in quality of life, which have 
paralleled the overactive bladder symptom reductions (Haab 
2005; Chapple 2006). Both ﬁ  xed and ﬂ  exible darifenacin 
dosing regimens produce these beneﬁ  cial effects, which 
extend to the more vulnerable population of older patients.
There may also be a place for incorporating patient-
initiated dose adjustment into the protocol (Staskin and 
MacDiarmid 2006a, 2006b). The primary care physician can 
then effectively manage adverse events associated with OAB 
without compromising efﬁ  cacy. Given some control in the 
process, patients are willing to tolerate certain side effects 
in exchange for symptom relief.
Conclusion
Evidence would suggest that darifenacin is an antimuscarinic 
drug particularly useful in the elderly population and 
therefore a useful addition to the current range of medications 
available on the market. Being an M3-speciﬁ  c antagonist, it 
is part of an important advance in the development of drugs 
for the treatment of OAB. Data from clinical trials have 
shown that darifenacin is efﬁ  cacious and well tolerated in 
addition to providing improvements in lower urinary tract 
symptoms with minimal CNS side effects. It also results in 
signiﬁ  cant improvements in quality of life scores. The dosage 
of drug also represents a compromise between efﬁ  cacy and 
Table 6 Outcome following 12 weeks of treatment in elderly patients (Foote et al 2005)
Efﬁ  cacy   Darifenicin   Placebo   Darifenacin   Placebo 
parameters   (7.5 mg QD)     (15 mg QD)   
Micturitions /day    −1.8(−18.2)    −0.6(−6.5)    −1.8(−16.9)    −1.0(−9.1) 
Incontinence episodes/week    −11.2(−66.7)    −4.8(−34.8)  −10.8(−75.9)    −6.8(−44.8)   
Number of urgency episodes/day    −2.1(−25.7)    −0.6(−6.6)    −2.4(−25.7)    −0.8(−10.4) 
Bladder capacity (mean vol voided mls)   14(10.4)   2(1.3)   27(18.0)   2(1.3) 
Notes: Results expressed as median (%) change from baseline to week 12; p<0.05 in improving all four efﬁ  cacy parameters (Wilcoxon rank-sum test, stratiﬁ  ed by study).
Abbreviations: QD, once daily. Clinical Interventions in Aging 2006:1(4) 315
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tolerability, and thus, it is important, particularly in the 
clinical setting, to have a range of doses that may then be 
tailored to patients’ individual needs. Darifenacin has been 
compared with immediate-release tolterodine, and further 
studies are warranted to compare the drug with the newer 
QD preparations of both oxybutynin and tolterodine to 
examine whether the theoretical advantages of an M3-speciﬁ  c 
antagonist translate into clinical practice. Compliance 
with medical therapy remains a significant problem in 
the treatment of the overactive bladder. When selecting 
an antimuscarinic agent for the management of an elderly 
patient presenting with OAB, in addition to considering 
evidence of clinical efﬁ  cacy and tolerability, issues of safety 
speciﬁ  c to an older population should be borne in mind. In 
particular, the likelihood of detrimental CNS effects should 
be considered, including cognitive impairment and sleep 
disturbances, secondary to anticholinergic load. Oxybutynin 
and tolterodine have both been associated with cognitive 
adverse events and effects on sleep architecture and quality. 
In contrast, darifenacin does not appear to be associated 
with cognitive adverse events and does not negatively affect 
sleep architecture or quality though it is just as if not more 
efﬁ  cacious (Kay et al 2006). Darifenacin in the treatment of 
the OAB represents a pharmacological advance as one of a 
new type and class of drug. 
This new addition to the armamentarium available for 
the management of OAB is welcome to both clinician and 
patient alike, and the evidence so far would suggest that 
darifenacin should have a major effect in this difﬁ  cult-to-
manage condition.
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